Concerto Biosciences

Meet the Start-Up Focused on Microbe-Tech: Concerto Biosciences. ?? From eczema to agriculture, Concerto Biosciences uses microbes to rewrite the playbook on health and sustainability. Discover how their kChip technology could make microbes the key to advanced biotech solutions in this episode of the Tech Optimist Podcast: https://lnkd.in/ej4gQ4jp.

Concerto's clinical trial, ENS-002 for Atopic Dermatitis in Adults, is now recruiting. The study site is in Austin, TX. If you are interested in learning more about it, you can connect with the research site here: https://lnkd.in/e_v7hY2C.

Eczema goes deeper than the skin—it impacts every part of life. The constant itch, sleepless nights, and harsh treatments weigh on millions of people. Introducing ENS-002, a groundbreaking microbial therapy from Concerto Biosciences. It leverages the skin’s natural bacteria to disarm S. aureus—a major trigger for eczema flares—without the risks of steroids or immunosuppressants. Watch our latest ENS-002 video featuring SAB members Peter Lio, MD, Tiffany Scharschmidt, MD, and Paul Blainey, PhD to learn how we’re transforming eczema care and advancing skin health.

??? We are excited to introduce the nine companies selected for our inaugural 2024 Healthcare and Technology Accelerator Program! These women are driving transformational solutions in key areas such as cancer diagnostics, antimicrobial resistance, and at-home diagnostics - each working to improve patient care and outcomes. Throughout this accelerator program, these companies will participate in a dynamic series of workshops, led by industry experts, and gain access to Springboard’s vast network of advisors to accelerate their growth and impact. Read more here: https://lnkd.in/gwx9xjBX Meet the 2024 Cohort: ? Phuong Jean Pham, Cellens Inc: Non-invasive cancer diagnostics powered by mechanobiology and machine learning. ? Cheri Ackerman, Concerto Biosciences: Unlocking microbial ecosystem insights for groundbreaking healthcare solutions. ? Julie B. Kennedy, RubyWell: Supporting family caregivers with financial stability through an intelligent, automated platform. ? Amanda (Curtis) Burkardt, PHIOGEN: Next-gen antibiotics tackling antimicrobial resistance. ? Pahini Pandya, Panakeia: AI-driven molecular biomarker analysis from H&E tissue images. ? Martha Sklavos PhD, PMP, PhD, Aloe Therapeutics: Enhancing immunotherapy for hard-to-treat solid tumors. ? Amy Urban DMD, DMD, Urban Innovations: Improving sleep quality with non-pharmacological solutions. ? Nathalya Mamane, RT MicroDx: Saliva-based at-home diagnostics for bacterial and viral pathogens. ? Adrianna Cantu, Revealix: Preventing diabetic foot complications through mobile thermography.

Concerto loves microbes, and we're not the only ones. Check out this article from the BBC: "Our skin is teeming with microbes. We should learn to love them." When our skin microbes work well together they fight infections, maintain hydration, accelerate wound healing, shield against UV radiation, and train the immune system. When microbes don't, they drive conditions like eczema, psoriasis, dandruff, acne, and even cancer. At Concerto, we show our love of microbes—and the people they live on—by “solving” the microbial ecology governing how microbes interact with each other to keep us healthy and then developing products that harness that power. Learn to love microbes? We couldn't agree more.

Women in Tech: Meet Cheri Ackerman, Co-Founder and CEO of Concerto Biosciences. Cheri is at the forefront of biotech innovation, using her expertise to create groundbreaking products that harness the complexity of the microbiome for health and agriculture. With a Ph.D. in Chemistry from University of California, Berkeley and postdoctoral work at the Broad Institute of MIT and Harvard, Cheri has developed high-throughput technologies for viral detection and microbial ecology. Her journey from NIH Postdoctoral Fellow to leading a #biotech startup showcases her dedication to scientific advancement and entrepreneurial spirit. Let’s celebrate Cheri’s passion for science and leadership in tech as she sets a powerful example for women aspiring to make their mark in the industry! #WomeninTech #MedTech #ScientificAdvancement #FemaleEntrepreneurs

On the latest episode of the Building Biotechs podcast, hosted by Carina Clingman, PhD, our CEO Cheri Ackerman shares Concerto’s perspective on building a business through iteration and optimization: All aspects of company creation, including the business model itself, can be treated as experiments. This framework is articulated in one of Concerto’s core values, grow by experimenting. Tune in to hear more about Concerto’s many experiments across business, science, and culture. Cheri also offers valuable fundraising advice and great book recommendations.

Wondering how Concerto thinks about AI, global health, the looming threat of antibiotic resistance, and how the kChip discovery platform fits into all of this? Find out in this feature from Bio.News. https://lnkd.in/eE5hZen6

Let's raise a glass to Concerto’s 4th anniversary as a company. For Gala_004, we gathered for a night of dazzling lights, a live quartet (4 musicians in honor of 4 years, of course), signature microbial cocktails, and absurd, wonderful, collaborative music making (see the pics!). Microbes are the performers of nature’s grandest symphony. We thank everyone—Concertians, advisors, investors, friends—who attended our birthday party to help celebrate them with us.

Drumroll please! Concerto Biosciences has officially secured an open Investigational New Drug (IND) application for Ensemble No.2 (ENS-002) First-In-Human clinical trials. In the biotech world, this is a pivotal moment, not only showcasing our technical rigor, but also representing a huge step toward improving patient lives with microbial treatments. Next stop: the clinic! https://lnkd.in/ek3BTYSk